Preclinical development
If you are moving from research into regulated development, early quality decisions matter more than they may first appear. The way studies are designed, documented, and governed in preclinical development directly affects whether your data can be relied upon and accepted later.
Quality oversight at this stage focuses on GLP principles, clear ownership, data traceability, and proportionate governance—without turning research into an administrative burden. Addressing quality early reduces the risk of repeat studies, regulatory questions, and delays when entering clinical development.
Why QAlliance
We work closely with research‑driven teams and biotech organisations, helping translate scientific excellence into preclinical data that stands up to regulatory scrutiny without over‑engineering quality too early.
Clinical development
As a sponsor or Investigator, you are accountable for the quality and integrity of your clinical trials. Each development phase builds on the previous one, and the data you generate becomes the foundation for regulatory decisions, approvals, and ultimately patient trust.
With ICH GCP E6 R3, quality is expected to be embedded into trial design from the outset. This includes defining critical‑to‑quality factors, performing structured risk assessments, and implementing oversight models that are proportionate to trial complexity. Gaps in oversight, resourcing, or governance can directly impact participant safety and data integrity.
Why QAlliance
We support sponsors, investigators, service providers and Phase 1 units with deep GCP expertise, helping design pragmatic oversight models and quality frameworks that meet regulatory expectations while remaining workable in day‑to‑day trial execution.
Pharmaceutical manufacturing
In pharmaceutical manufacturing, quality is demonstrated every day through controlled processes, validated systems, and disciplined execution. From early‑stage manufacturing to commercial supply, regulators expect you to maintain a continuous state of control.
GMP compliance requires clear governance, effective change control, robust deviation and CAPA management, and constant inspection readiness. Strong quality systems do not only protect patients—they also support efficient operations and reliable supply.
Why QAlliance
We have extensive hands‑on experience in GMP environments, including QP and RP responsibilities, and we help manufacturers maintain control, prepare for inspections, and scale operations with confidence.
Analytical and medical laboratories
If you are responsible for a laboratory, confidence in results depends on much more than technical capability. Accreditation bodies expect you to demonstrate impartiality, competence, traceability, and effective quality management — every day.
Standards such as GLP, GCLP, ISO 17025 and ISO 15189 place equal emphasis on scientific validity, organisational control, and a safe working environment. Sustainable compliance requires systems that support people rather than overwhelm them.
Why QAlliance
We have deep experience working with analytical and medical laboratories, supporting GLP and ISO accreditation or certification with practical solutions that strengthen quality, safety, and confidence in results.
Quality systems, audits and inspections
If you are accountable for quality across an organisation, you need systems that provide visibility, control, and confidence. Quality management systems, audits, and governance structures together demonstrate that risks are understood and controlled.
Regulatory expectations increasingly focus on risk‑based approaches, active management involvement, and effective internal oversight. Audits and inspections should confirm a state of control—not expose surprises.
Why QAlliance
We design and assess quality systems from a regulator’s perspective, drawing on our experience as senior auditors and former inspectors to help maintain oversight and inspection readiness at all times.
Life Science startups and scale‑ups
When building or scaling a life science company, quality can feel like a barrier to speed. In reality, the right level of quality enables growth, partnerships, and investment—while poor early decisions often lead to costly rework later.
Fit‑for‑purpose quality systems allow regulatory expectations to be met without slowing innovation. Proportionate controls and early guidance help manage risk as complexity increases.
Why QAlliance
We have extensive experience supporting life science startups and scale‑ups, helping leadership teams build quality foundations that support growth, credibility, and long‑term success.
Due diligence and acquisitions
In mergers, acquisitions, partnerships and co-sponsorship, quality and regulatory maturity are often decisive factors. Undetected compliance gaps can affect valuation, delay closing, or create significant post‑transaction risk.
Quality‑focused due diligence provides insight into development, manufacturing, and clinical operations, enabling informed decisions and realistic integration planning.
Why QAlliance
We support investors, buyers, and sellers with an independent, quality‑driven perspective, helping identify regulatory and quality risks early and support compliant, efficient integration after the transaction. We can also support with change of sponsorship in clinical trials.
